Antiplatelet use for CVD prevention

Dual antiplatelet therapy is beneficial for secondary prevention in patients at high risk of cardiovascular disease, but not for primary prevention, according to data presented at the conference.

The Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilisation, Management and Avoidance (CHARISMA) trial of 15,603 patients with multiple cardiovascular risk factors found more deaths from cardiovascular causes in patients on 75mg/day clopidogrel plus low-dose aspirin compared to patients on low-dose aspirin only.

In secondary prevention, combined therapy was associated with a 12 per cent reduction in rates of MI, stroke or death.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus